Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on May 27, 2021 12:00pm
55 Views
Post# 33275868

RE:RE:RE:RE:RE:RE:RE:RE:More volume/higher valuation? This is how to get there.

RE:RE:RE:RE:RE:RE:RE:RE:More volume/higher valuation? This is how to get there.While most NASH companies are in red today HEPA is up almost 6%, so these sort of interactions with the market does work. Now the trick is to keep it coming before the story fades away. If you look at yahoo finance HEPA has actively been attending multiple conferences are still doing it.
As mentioned by others it has always been a hole in the news flow so they need to fil those holes to keep their story relevant until new news are announced. Occasionally we get a pop in both volume and valuation and then the slow bleed.
To me marketing and messaging should be an ongoing operation which will be the key to rebranding of the company. Seeking alpha has produced a follow up article from the interview with HEPA's CEO. So they are constantly promoting their business. I hope the re-engineering plan includes comprehensive efforts to communicate with whole market on a regular and frequent basis.
  

<< Previous
Bullboard Posts
Next >>